The 2011 ACCF/AHA guideline provides expert analysis of available data to optimize care and outcomes for patients with hypertrophic cardiomyopathy.
Provides the 2011 ACCF/AHA clinical practice guidelines for the diagnosis and management of hypertrophic cardiomyopathy.
It is essential that the medical profession play a central role in critically evaluating the evidence related to drugs, devices, and procedures for the detection, management, or prevention of disease. Properly applied, rigorous, expert analysis of the available data documenting absolute and relative benefits and risks of these therapies and procedures can improve the effectiveness of care, optimize patient outcomes, and favorably fnect the cost of care by focusing resources on the most effective strategies.
Gersh et al. (Fri,) conducted a review in Hypertrophic cardiomyopathy. The 2011 ACCF/AHA guideline provides expert analysis of available data to optimize care and outcomes for patients with hypertrophic cardiomyopathy.